Protalix BioTherapeutics (PLX) Reports Q4 Loss of $0.29/Share
Get Alerts PLX Hot Sheet
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.29), versus ($0.36) reported last year. Revenue for the quarter came in at $4.4 million, versus $3.5 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- VNET Group (VNET) Tops Q4 EPS by 18c, provides guidance
- Celcuity (CELC) Tops Q4 EPS by 16c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!